Clinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine

Heart

Volumn 98, Issue 6, 2012, Pages 443-449

  Oh, Yingzi ^a   Wei, Heming ^b   Dongrui, Ma ^b   Sun, Xiaoming ^b   Liew, Reginald ^a,b  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; CALCIUM ION; NICORANDIL; NIFEDIPINE; PD 118057; PINACIDIL; POTASSIUM CHANNEL STIMULATING AGENT; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ACTION POTENTIAL; AUTOSOMAL DOMINANT INHERITANCE; BIOLOGICAL PACEMAKER; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; DRUG SCREENING; EMBRYOID BODY; EMBRYONIC STEM CELL; GENE; HEART MUSCLE CELL; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INTRACELLULAR SIGNALING; KCNQ1 GENE; LEOPARD SYNDROME; LONG QT SYNDROME; MISSENSE MUTATION; NONHUMAN; PACEMAKER; PERSONALIZED MEDICINE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TISSUE REPAIR;

CARDIOLOGY; CARDIOVASCULAR DISEASES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, BIOLOGICAL; MYOCYTES, CARDIAC; REGENERATIVE MEDICINE;

EID: 84862777929     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-301317     Document Type: Review

References (48)

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76. (Pubitemid 44233629)
2. Freund C, Mummery CL. Prospects for pluripotent stem cell-derived cardiomyocytes in cardiac cell therapy and as disease models. J Cell Biochem 2009;107:592-9.
3. Narsinh K, Narsinh KH, Wu JC. Derivation of human induced pluripotent stem cells for cardiovascular disease modeling. Circ Res 2011;108:1146-56.
4. Wu SM, Hochedlinger K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol 2011;13:497-505.
5. Inoue H, Yamanaka S. The use of induced pluripotent stem cells in drug development. Clin Pharmacol Ther 2011;89:655-61.
6. Ebert AD, Yu J, Rose FF Jr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009;457:277-80.
7. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321:1218-21.
8. Liu GH, Barkho BZ, Ruiz S, et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 2011;472:221-5.
9. Moretti A, Bellin M, Welling A, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010;363:1397-409.
10. Itzhaki I, Maizels L, Huber I, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011;471:225-9.
11. Matsa E, Rajamohan D, Dick E, et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 2011;32:952-62.
12. Yazawa M, Hsueh B, Jia X, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011;471:230-4.
13. Carvajal-Vergara X, Sevilla A, D'Souza SL, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010;465:808-12.
14. Ma D, Wei H, Guangqin Z, et al. Generation of induced pluripotent stem cells and cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy [abstract]. Circulation 2011;124:21. Supplement (A12906).
15. Ng KM, Lee YK, Lai WH, et al. Exogenous expression of human apoA-I enhances cardiac differentiation of pluripotent stem cells. PLoS One 2011;6:e19787.
16. Paige SL, Osugi T, Afanasiev OK, et al. Endogenous Wnt/beta-catenin signaling is required for cardiac differentiation in human embryonic stem cells. PLoS One 2010;5:e11134.
17. Sarig U, Machluf M. Engineering cell platforms for myocardial regeneration. Expert Opin Biol Ther 2011;11:1055-77.
18. Alford PW, Feinberg AW, Sheehy SP, et al. Biohybrid thin films for measuring contractility in engineered cardiovascular muscle. Biomaterials 2010;31:3613-21.
19. Braam SR, Tertoolen L, van de Stolpe A, et al. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res 2010;4:107-16.
20. Caspi O, Itzhaki I, Kehat I, et al. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev 2009;18:161-72.
21. Collin J, Lako M. Concise review: putting a finger on stem cell biology: zinc finger nuclease-driven targeted genetic editing in human pluripotent stem cells. Stem Cells 2011;29:1021-33.
22. Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011;478:391-4.
23. Sebastiano V, Maeder ML, Angstman JF, et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 2011;29:1717-26.
24. Lovell MJ, Mathur A. Cardiac stem cell therapy: progress from the bench to bedside. Heart 2010;96:1531-7.
25. Yoshida Y, Yamanaka S. iPS cells: a source of cardiac regeneration. J Mol Cell Cardiol 2011;50:327-32.
26. Pera MF. Stem cells: the dark side of induced pluripotency. Nature 2011;471:46-7.
27. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007;318:1920-3.
28. Wernig M, Zhao JP, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 2008;105:5856-61. (Pubitemid 351758462)
29. Xu D, Alipio Z, Fink LM, et al. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci U S A 2009;106:808-13.
30. Nelson TJ, Martinez-Fernandez A, Yamada S, et al. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation 2009;120:408-16.
31. Mauritz C, Martens A, Rojas SV, et al. Induced pluripotent stem cell (iPSC)-derived Flk-1 progenitor cells engraft, differentiate, and improve heart function in a mouse model of acute myocardial infarction. Eur Heart J 2011;32:2634-41.
32. Kehat I, Khimovich L, Caspi O, et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol 2004;22:1282-9. (Pubitemid 39341201)
33. Xue T, Cho HC, Akar FG, et al. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. Circulation 2005;111:11-20. (Pubitemid 40070838)
34. Huber I, Itzhaki I, Caspi O, et al. Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. FASEB J 2007;21:2551-63. (Pubitemid 47230684)
35. Hattori F, Chen H, Yamashita H, et al. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat Methods 2010;7:61-6.
36. Margariti A, Winkler B, Karamariti E, et al. Direct reprogramming fibroblasts into endothelial cells [abstract]. Heart 2011;97:e7.
37. Efe JA, Hilcove S, Kim J, et al. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol 2011;13:215-22.
38. Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010;142:375-86.
39. Liao SY, Liu Y, Siu CW, et al. Proarrhythmic risk of embryonic stem cell-derived cardiomyocyte transplantation in infarcted myocardium. Heart Rhythm 2010;7:1852-9.
40. Menasche P. Stem cell therapy for heart failure: are arrhythmias a real safety concern? Circulation 2009;119:2735-40.
41. Johnston PV, Sasano T, Mills K, et al. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation 2009;120:1075-83, 7.
42. Shimizu T, Sekine H, Yamato M, et al. Cell sheet-based myocardial tissue engineering: new hope for damaged heart rescue. Curr Pharm Des 2009;15:2807-14.
43. Burridge PW, Thompson S, Millrod MA, et al. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One 2011;6:e18293.
44. Fujiwara M, Yan P, Otsuji TG, et al. Induction and enhancement of cardiac cell differentiation from mouse and human induced pluripotent stem cells with cyclosporin-A. PLoS One 2011;6:e16734.
45. Rufaihah AJ, Huang NF, Jame S, et al. Endothelial cells derived from human iPSCS increase capillary density and improve perfusion in a mouse model of peripheral arterial disease. Arterioscler Thromb Vasc Biol 2011;31:e72-9.
46. Schmidt D, Dijkman PE, Driessen-Mol A, et al. Minimally-invasive implantation of living tissue engineered heart valves: a comprehensive approach from autologous vascular cells to stem cells. J Am Coll Cardiol 2010;56:510-20.
47. Dick E, Matsa E, Young LE, et al. Faster generation of hiPSCs by coupling high-titer lentivirus and column-based positive selection. Nat Protoc 2011;6:701-14.
48. Zhang Z, Gao Y, Gordon A, et al. Efficient generation of fully reprogrammed human iPS cells via polycistronic retroviral vector and a new cocktail of chemical compounds. PLoS One 2011;6:e26592.